🔎 Trials Near Me

Beranda › Mieloma Multipel › Louisiana

Uji klinis Mieloma Multipel di Louisiana

9 studi untuk Mieloma Multipel mencari peserta di lokasi di Louisiana.

Kota di Louisiana

Teks studi resmi (Bahasa Inggris)

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

  • Local Institution - 0385, Shreveport
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT05519085

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  • LSU Health Feist Weiller Cancer Center, Shreveport
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07518186

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

  • Mary Bird Perkins Cancer Center, Baton Rouge
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07609940

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  • LSUHSC Shreveport Feist-Weiller Cancer Center, Shreveport
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05552222

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  • Louisiana State University Health Sciences Shreveport, Shreveport
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06615479

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

  • GSK Investigational Site, Baton Rouge
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT07227311

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  • Research Site, Baton Rouge
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT07764978

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Tulane University School of Medicine /ID# 251204, New Orleans
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT05650632

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.